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ABSTRACT
Objective To examine in a randomised trial whether a
25% difference in mortality exists between 4.5 months
and 3 years of age for children given two standard doses
of Edmonston-Zagreb measles vaccines at 4.5 and
9 months of age compared with those given one dose of
measles vaccine at 9 months of age (current policy).
Design Randomised controlled trial.
SettingTheBandimHealthProject,Guinea-Bissau,which
maintains a health and demographic surveillance system
in an urban area.
Participants 6648 children aged 4.5 months of age who
had received three doses of diphtheria-tetanus-pertussis
vaccine at least four weeks before enrolment. A large
proportion of the children (80%) had previously taken
part in randomised trials of neonatal vitamin A
supplementation.
Intervention Children were randomised to receive
Edmonston-Zagreb measles vaccine at 4.5 and 9 months
of age (group A), no vaccine at 4.5 months and
Edmonston-Zagreb measles vaccine at 9 months of age
(group B), or no vaccine at 4.5 months and Schwarz
measles vaccine at 9 months of age (group C).
Mainoutcomemeasure Mortality rate ratio between 4.5
and36monthsofageforgroupAcomparedwithgroupsB
and C. Secondary outcomes tested the hypothesis that
the beneficial effect was stronger in the 4.5 to 9 months
age group, in girls, and in the dry season, but the study
was not powered to test whether effects differed
significantly between subgroups.
Results In the intention to treat analysis of mortality
between4.5and36monthsofagethemortalityrateratio
of children who received two doses of Edmonston-Zagreb
vaccine at 4.5 and 9 months of age compared with those
who received a single dose of Edmonston-Zagreb vaccine
or Schwarz vaccine at 9 months of age was 0.78 (95%
confidence interval 0.59 to 1.05). In the analyses of
secondary outcomes, the intention to treat mortality rate
ratio was 0.67 (0.38 to 1.19) between 4.5 and 9 months
and 0.83 (0.83 to 1.16) between 9 and 36 months of age.
Theeffectonmortalitybetween4.5and36monthsofage
was significant for girls (intention to treat mortality rate
ratio 0.64 (0.42 to 0.98)), although this was not
significantlydifferentfromtheeffectinboys(0.95(0.64to
1.42)) (interaction test, P=0.18). The effect did not differ
betweenthedryseasonandtherainyseason.Asneonatal
vitamin A supplementation is not WHO policy, the
analyses were done separately for the 3402 children who
did not receive neonatal vitamin A. In these children, the
two dose Edmonston-Zagreb measles vaccine schedule
was associated with a significantly lower mortality
between 4.5 and 36 months of age (intention to treat
mortality rate ratio 0.59 (0.39 to 0.89)). The effect was
again significant for girls but not statistically significant
from the effect in boys. When measles cases were
censored, the intention to treat mortality rate ratio was
0.65 (0.43 to 0.99).
Conclusions Although the overall effect did not reach
statisticalsignificance,theresultsmayindicatethatatwo
dose schedule with Edmonston-Zagreb measles vaccine
given at 4.5 and 9 months of age has beneficial non-
specific effects on children’s survival, particularly for girls
and for children who have not received neonatal vitamin
A. This should be tested in future studies in different
locations.
Trial registration Clinical trials NCT00168558.
INTRODUCTION
Whenmeaslesvaccinewasintroducedatdemographic
surveillance sites in Africa in the late 1970s and early
1980s, several studies reported major reductions in
childhood mortality of 40% or more.
1-7 Population
based studies in Bangladesh and Haiti gave similar
results.
8-10 The effect was much larger than expected,
as measles infection caused much less than 40% of the
deaths in these communities. These observations sug-
gested that measles vaccine may have non-specific
beneficial effects that provide protection against infec-
tions other than measles.
11
An implication of these observations was that low-
ering the age of measles vaccination might be benefi-
cial. The World Health Organization set the age of
measles vaccination at 9 months to minimise inter-
ference from maternal antibodies.
12 However,
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measlesvaccinecanbeusedeffectivelyeveninthepre-
sence of maternal antibodies.
1314 In the mid-1980s, we
therefore did several trials in the Gambia, Guinea-
Bissau,andSenegal,inwhichchildrenwerevaccinated
at 4-5 months of age with medium titre or high titre
Edmonston-Zagreb measles vaccine.
13-18 WHO
recommended the high titre version of the Edmon-
ston-Zagrebvaccineforroutineusein1989.However,
the West African trials surprisingly showed that early
Edmonston-Zagreb vaccination at 4-5 months of age
was associated with twofold higher mortality in
girls.
1819 After these results were confirmed in Haiti,
20
WHO rescinded its recommendation for the use of
hightitremeaslesvaccinein1992.
21Hightitremeasles
vaccine was fully protective against measles, and these
trials therefore showed that high titre measles vaccine
had non-specific and sex differential effects on chil-
dren’s survival.
19 Nevertheless, few attempts were
made to explain these effects, and the major funding
institutions invested in the development of new
measles vaccines.
We pursued the hypothesis that standard titre
measles vaccine given in a two dose schedule at 6 and
9 monthsof agecould overcomethe interferencefrom
maternal antibodies and be fully protective against
measles infection and could have beneficial non-
specific effects on overall survival between 6 and
9monthsofage.
21-25Theresultsofourfirstrandomised
trial of two dose vaccine were disappointing; com-
pared with inactivated polio vaccine, which was used
as a control vaccine, the mortality rate ratio for early
measlesvaccineat 6 monthsof agewas 0.90 (95% con-
fidence interval 0.67 to 1.22) between 6 and 9 months
of age.
25 However, the study design had not taken
account of the interaction with diphtheria-tetanus-per-
tussis(DTP)vaccine.DTPvaccinehasbeenassociated
with increased mortality in girls.
25 Among girls who
had received all three doses of DTP vaccine before
enrolmentandwerethereforeunlikelytoreceiveaddi-
tional dosesof DTP vaccine during follow-up,measles
vaccine tended to have a beneficial effect compared
with inactivated polio vaccine.
25 However, girls vacci-
nated with measles vaccine who were missing doses of
DTP vaccine at enrolment and were likely to receive
additional doses during follow-up had twofold higher
mortality than did girls who had received three doses
of DTP vaccine before enrolment.
25 We speculated
that DTP vaccine after measles vaccine could also
have been the explanation for the increased mortality
in girls after high titre measles vaccine
19: high titre
measles vaccine had been administered early, and
most children had received DTP/inactivated polio
vaccine after high titre measles vaccine. When we re-
examined the original dataset, we saw no excess mor-
tality in girls among children who had not received
DTP/inactivated polio vaccine after high titre measles
vaccine but a twofold higher mortality in girls among
childrenwhohadreceivedDTP/inactivatedpoliovac-
cine after high titre measles vaccine.
19
On the basis of these observations, we started a sec-
ondtrialoftwodosevaccinein2003,randomisingchil-
dren toa standarddoseof Edmonston-Zagrebmeasles
vaccine at 4.5 and 9 months of age or no vaccine at 4.
5 months and measles vaccine at 9 months of age.
2627
To prevent the interference from DTP vaccinations
administered after measles vaccine, only children
who had received all three doses of DTP vaccine
were enrolled in the trial. To ensure that an interval
of at least four weeks existed between the third DTP
vaccineandmeaslesvaccine,theearliestwecouldvac-
cinate against measles was at 4.5 months of age. Our
hypothesis was that early measles vaccine would have
a beneficial effect, particularly for girls. We aimed to
measure the effect of measles vaccine at 4.5 and
9 months of age on survival between 4.5 months and
3yearsofage,comparedwithnovaccineat4.5months
of age and either Edmonston-Zagreb or Schwarz
measlesvaccineat9monthsofageascurrentlyrecom-
mended by WHO. All participants have now reached
3 years of age, and we therefore report the effect of
early measles vaccination on overall mortality
between 4.5 months and 3 years of age.
METHODS
Setting and study population
The trial took place in Guinea-Bissau in the Bandim
Health Project’s study area, which covers six districts
with approximately 102000 inhabitants—that is, 30%
of the population of the capital Bissau.
28 All residents
have an identification number in the census files, and
information on the place of residence can be retrieved
from these files, along with socioeconomic and demo-
graphic information. All houses are visited every
month to registernew pregnanciesand births. All chil-
dren are visited at home every three months until the
ageof3years;atthesevisits,wecollectinformationon
breastfeeding status, infections, hospital admissions,
vaccination status, living with the mother, and owner-
ship of pigs. Three health centres in the project area
provide routine vaccinations. At the beginning of this
trial, the coverage for the third DTP vaccine was 89%
and that for measles vaccine was 88% among children
aged 12-23 months of age.
29
During the trial period from 2003 to 2009, many
government driven health intervention campaigns
occurred, as is now usual in Guinea-Bissau and other
West African countries. We had field assistants who
accompanied all the campaign teams in the study
area to monitor who received the interventions
(table 1). Two measles vaccination campaigns took
place in May 2006 and July 2009. With permission
from the Ministry of Health, the study participants
were excluded from these campaigns (see web table
A). Participants in the trial could have taken part in
other randomised trials in the area (table 1 and web
table A).
30-32 Thus, even though the two dose measles
trial was randomised, we needed to examine in sub-
analyses the effects that these other interventions may
have had on the main intervention.
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Theprimary objective of this study was to measurethe
effect of different strains and schedules of measles
vaccination on overall mortality between 4.5 and
36 months of age. The sample size was based on the
hypothesis that we should be able to measure a 25%
difference in mortality between early measles vaccina-
tion and the current policy of measles vaccination at
9monthsofage.Thesecondaryobjectivesweretomea-
sure mortality between 4.5 and 9 months of age and
between 9 and 36 months of age and to determine the
possibleeffectofsexandseason.Wehypothesisedthat
the non-specific beneficial effects would be strongest
for girls and in the dry season. However, we could not
power the study to testa significant difference between
girls and boys and between dry and rainy seasons.
Thetrialincludedthreearms:twodosemeaslesvac-
cination providing standard dose Edmonston-Zagreb
measles vaccine at 4.5 and 9 months of age (group A),
no vaccine at 4.5 months and standard dose Edmon-
ston-Zagrebmeaslesvaccineat9monthsofage(group
B), and no vaccine at 4.5 months and standard dose
Schwarz measles vaccine at 9 months of age (group
C). All children were enrolled and randomised at 4.
5 months of age. Because a condition for entering the
trial was that the children had received the third DTP
vaccine at least four weeks before enrolment, the chil-
dren in groups B and C had the third DTP vaccine as
their most recent vaccination between 4.5 and
9monthsofage.Wehavepreviouslyreportedtheclin-
ical protection of one dose of measles vaccine at 4.
5monthsofage
26;thefirstdoseofmeaslesvaccineat4.
5 months of age was highly protective against clinical
measlesinfectionand100%protectiveagainsthospital
admissionformeasles(95%confidenceinterval46%to
100%) and death from measles (−42% to 100%). By
24 months of age, all the 925 children tested in the
study had responded with specific antibodies to
measles vaccination; 97% in group A, 99% in group
B,and99%ingroupChadprotectivelevelsofmeasles
antibodies (unpublished data).
The WHOimmunisation programmeuses standard
dose Edmonston-Zagreb and Schwarz measles vac-
cines interchangeably. However, if vaccines have
non-specific effects,
1119 these could differ between
two strains of measles vaccine with very different bio-
logical qualities, including that Edmonston-Zagreb is
more immunogenic than Schwarz in the presence of
maternal antibodies.
23 We therefore intended to com-
pare the effect on children’s survival of these two
strains by comparing groups B and C. We used the
early two dose measles vaccination schedule to exam-
ine whether effective vaccination at 4.5 months and
9monthsofagewithlongtermmaintenanceofmeasles
antibodies was possible and to study whether measles
vaccine compared with the third DTP vaccine had
non-specific beneficial effects for child health by com-
paringgroupAwithgroupsBandC.Wehypothesised
that a beneficial effect would be particularly important
for girls. We present the results of this analysis here.
Table 1 |Background factors for early two dose measles vaccine (group A) and measles
vaccine at 9 months (groups B+C). Values are percentages (numbers) unless stated
otherwise
Early two dose
measles vaccine
(group A; n=2129)
Measles vaccine at
9 months (groups B
and C; n=4288)
Demographic factors
Median (interquartile range) age at enrolment (months) 4.8 (4.7-5.2) 4.8 (4.7-5.2)
Median (interquartile range) age of mother (years) 25 (21-29) 25 (20-29)
Bandim district 42 (898) 42 (1794)
Male sex 51 (1084) 50 (2151)
Twins 3.6 (77) 3.4 (145)
Pepel ethnicity 31 (662) 29 (1224)
Mother died (No) 3 8
Risk factors at enrolment
Not breast fed at 4.5 months 3.3 (71) 3.5 (150)
Pigs in household 16 (343) 17 (739)
No of people/bed 2.9 2.9
No of people/sleeping room 4.1 4.2
Toilet inside house 16 (338) 15 (632)
Functioning electricity 25 (537) 26 (1111)
Hospital admission before enrolment 3.9 (83) 3.8 (162)
Morbidity and anthropometry at enrolment
Fever 8.4 (178) 9.4 (403)
Diarrhoea 4.7 (101) 4.4 (188)
Mean respiratory frequency 42 43
BCG scar 86 (1832) 86 (3673)
Have chloroquine at home 35 (745) 33 (1408)
Mean (SD) weight (g) 7153 (988) 7134 (998)
Mean (SD) arm circumference (mm) 142 (12) 142 (12)
Mean (SD) height (cm) 64.1 (2.8) 64.1 (2.8)
Mean (SD) mother’s arm circumference (mm) 275 (34) 274 (34)
Participation in other trials and campaigns*
LBW trial 6.3 (134) 6.3 (268)
First vitamin A trial 34 (719) 34 (1466)
Second vitamin A trial 44 (944) 44 (1883)
DTP booster trial 52 (1109) 53 (2269)
Measles vaccine campaign 2006 3.1 (65) 3.2 (139)
Measles vaccine campaign 2009 1.6 (35) 1.4 (60)
Bed net distribution 2006 44 (928) 42 (1817)
Bed net distribution 2007 41 (870) 38 (1637)
Bed net impregnation 2006 24 (516) 23 (1004)
Bed net impregnation 2007 26 (564) 26 (1103)
OPV campaign 2004 40 (844) 39 (1663)
OPV campaign 2005 59 (1251) 58 (2507)
VAS campaign 2004 26 (553) 25 (1077)
VAS campaign 2005 46 (971) 45 (1949)
First VAS campaign 2006† 56 (1187) 56 (2404)
Second VAS campaign 2006 38 (818) 37 (1597)
First VAS campaign 2007 48 (1016) 47 (1994)
Second VAS campaign 2007 34 (729) 35 (1503)
First VAS campaign 2008 22 (458) 23 (989)
Second VAS campaign 2008 43 (918) 43 (1854)
First VAS campaign 2009 27 (574) 27 (1155)
DTP= diphtheria-tetanus-pertussis; LBW=low birth weight; OPV=oral polio vaccine; VAS=vitamin A
supplementation.
*All campaigns in study population were monitored to assess possible interactions; field assistants
accompanied all campaign teams in study area.
†From 2006 onwards vitamin A supplementation campaigns have included treatment with mebendazole for
children aged 1-4 years.
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tional visit at 18 months and randomised them to an
additionaldoseofthesamestrainofmeaslesvaccineor
no additional dose to examine whether the additional
dose had an effect on the long term maintenance of
measles antibody concentrations. The additional dose
hadnoeffectonantibodyconcentrations(unpublished
data). We found no difference in mortality between
18 months and 36 months of age in children who
received an additional dose and those who did not
(fig 1). We have therefore not further divided the chil-
dren in group B and C into those who received or did
not receive an additional dose of measles vaccine.
Sample size
Webasedthesamplesizeonthecalculationthat,witha
powerof80%,asignificancelevelof5%,andanannual
mortality rate of 50 per 1000 person years, we needed
4360personyearsineachgrouptodetecta25%differ-
enceinmortalityfrom4.5to36monthsofagebetween
anytwoofthethreegroups.Withanexpected10%loss
to follow-up and an average follow-up of 30 months,
we needed 1918 children in each arm of the study.
Owing to additional immunological studies, we
enlarged the cohort to include 6648 children. As all
children were treated according to the original proto-
col until 3 years of age, we analysed mortality for the
complete cohort.
Enrolment, informed consent, and randomisation
Study procedures have been described in detail in a
previous paper.
26 We identified newborn infants in
the Bandim Health Project registration system and
remindedmotherstobringtheirchildrenforDTPvac-
cinationat6,10,and14weeksofage.Enrolmentinthe
measlesvaccinationtrialoccurredat4.5monthsofage.
To facilitate access of the local populations, enrolment
was organised by the same team of physician, nurses,
and field workers on different weekdays at the three
local health centres. The mothers or guardians of chil-
dren presenting at the local health centre received an
oral and a written explanation of the study from a doc-
tor. They were told that which measles vaccine strain
or vaccination strategy was best was not known. At
each visit tothe health centre,the doctor dida medical
examination.
Controls (groups B+C) randomised at 4.5 months (n=4437) EZ group (group A) randomised at 4.5 months (n=2211)
Followed up and analysed (n=4288) Followed up and analysed (n=2129)
DTP3 vaccinated children randomised at local health centres (n=6648)
No VAS at birth
  Moved (n=87)
  Travelled (n=68)
  Refused (n=9)
  MV elsewhere (n=139)
  Sick (n=0)
  Missing forms (n=12)
  Wrong vaccine (n=5)
  Died (n=29)
Vaccinated at 9 months (n=1946)
VAS at birth
  Moved (n=67)
  Travelled (n=41)
  Refused (n=5)
  MV elsewhere (n=123)
  Sick (n=1)
  Missing forms (n=8)
  Wrong vaccine (n=9)
  Died (n=19)
Vaccinated at 9 months (n=1720)
No VAS at birth
  Moved (n=36)
  Travelled (n=34)
  Refused (n=1)
  MV elsewhere (n=11)
  Sick (n=0)
  Missing forms (n=4)
  Wrong vaccine (n=2)
  Died (n=5)
Vaccinated at 9 months (n=1014)
VAS at birth
  Moved (n=26)
  Travelled (n=22)
  Refused (n=2)
  MV elsewhere (n=8)
  Sick (n=1)
  Missing forms (n=5)
  Wrong vaccine (n=1)
  Died (n=11)
Vaccinated at 9 months (n=946)
Excluded (n=82):
  Previous measles (n=35)
  DTP3 interval (n=43)
  Double enrolment (n=4)
Excluded (n=149):
  Previous measles (n=45)
  DTP3 interval (n=88)
  Double enrolment (n=16)
Allocation
Follow-up
Outcomes
4-9 months
Moved (n=82)
Died (n=38 (PP); n=40 (ITT))
Moved (n=62)
Died (n=22 (PP); n=22 (ITT))
Moved (n=35)
Died (n=8 (PP); n=9 (ITT))
Moved (n=40)
Died (n=12 (PP); n=14 (ITT))
Outcomes
9-18 months
Randomised at 18 months
Booster MV (n=760; 9 died)*
No booster MV (n=766; 10 died)*
Not randomised (n=110; 3 died)
Still in area (n=1410)
Moved (n=204)
Died (n=22 (PP); n=25 (ITT))
Randomised at 18 months
Booster MV (n=838; 11 died)*
No booster MV (n=833; 12 died)*
Not randomised (n=155; 6 died)
Still in area (n=1542)
Moved (n=225)
Died (n=29 (PP); n=30 (ITT))
Still in area (n=834)
Moved (n=125)
Died (n=12 (PP); n=15 (ITT))
Still in area (n=769)
Moved (n=115)
Died (n=10 (PP); n=11 (ITT))
Outcomes
18-36 months
Exclusions
Fig 1 | Trial diagram for early two dose measles vaccination trial. DTP3=third diphtheria-tetanus-pertussis vaccine;
EZ=Edmonston-Zagreb vaccine; ITT=intention to treat analysis; MV=measles vaccine; PP=per protocol analysis; VAS=vitamin A
supplementation. *Children in groups B and C were randomised to receive or not receive a booster dose of same measles
vaccine at 18 months of age; deaths in parenthesis are number of deaths between randomisation at 18 months of age and
end of the study; these deaths are included in total for group
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dians were asked to select an envelope with the alloca-
tion number that defined to which group the child
belonged. We randomised children to one of three
equal sized groups by using block randomisation with
24 envelopes per bag. Block randomisation was orga-
nised within the whole study area and not by health
centre. Study participants had access to free consulta-
tions at the local health centres and to essential drugs
free of charge.
Intervention
Children randomised to group A received a standard
titreEdmonston-ZagrebvaccinefromtheSerumInsti-
tuteofIndia,Pune,India,at4.5and9monthsofage.At
9 months of age, the children in group B received the
same Edmonston-Zagreb measles vaccine, and chil-
dren in group C received a Schwarz measles vaccine
(Rouvax) from Pasteur Merieux, France.
Masking
As described previously, no placebo was given.
26 We
have previously used inactivated polio vaccine as a
control vaccine in trials of early measles
vaccination.
25 However, inactivated polio vaccine
andotherinactivatedvaccinesmayincreasethefemale
to male mortality ratio,
25 so we could not use a control
vaccine if we were to measure the non-specific effects
of measles vaccine. If we had used a placebo, some
mothers in the control group might erroneously have
believed that the child had received measles vaccine.
As long as they remained in the study area this would
matter little, as they would all be called for measles
vaccination at 9 months of age. However, if they
moved from the area they might not have gone to
another health centre to seek measles vaccination.
We therefore preferred to use no placebo. Mothers in
the control group were told that their children would
notreceivemeaslesvaccineatenrolment,butthatthey
should receive measles vaccine at 9 months of age.
Measurement of mortality
Mortality between 4.5 and 9 months of age—All children
were invited back to the health centre at 9 months of
age.Ifthechildrenwerenotathomeorweretravelling,
we kept calling the children until they were 18 months
of age.
Mortality between 9 and 36 months of age—All children
were invited back to the health centre at 24 months of
age, and all children were visited at home after
36 monthsof ageby theBandim HealthProject demo-
graphic surveillance system.
At these visits we obtained information about
whether the children had died or moved: we followed
childrenwhomovedwithinthestudyareatotheirnew
address, and we censored children who moved out of
the area in the survival analysis at the time of moving.
Mothers and their children travel frequently to visit
family in the rural areas or to take part in the harvest
of cashew nuts. However, information on survival is
always available; if a child dies in the rural areas, the
family in Bissau is informed immediately.
Change in context: measles epidemic
Ameaslesoutbreakbeganduringtheearlyphaseofthe
trial in October 2003 and lasted until May 2004. This
epidemic was unexpected because Bandim Health
Project has kept a very high coverage for measles vac-
cination for children under 3 years of age for many
years in this community.
26 However, the coverage of
vaccination had generally declined in the city, and
many older and presumably unvaccinated children
had moved in from rural areas. The epidemic and
measles surveillance during the epidemic has been
described elsewhere,
2629 and we tested the efficacy of
measles vaccine at 4.5 months of age during the
epidemic.
26 During the study, 110 children were diag-
nosed as having measles: 71 cases were confirmed by
serology, 10 did not have complete serology but were
diagnosed as definite measles by clinicians, and 29
were diagnosed by the mother. For this study, we
used the data on measles cases to censor for measles
infection in the survival analysis to obtain an estimate
of the effect of measles vaccineon non-measles related
mortality. By censoring all cases of measles at the time
ofmeaslesinfection,weexcludedfromthecomparison
not only deaths from acute measles but also potential
long term excess mortality after measles infection.
Statistical analyses
We entered data daily. We proofread important vari-
ablesandassuredconsistencywiththegeneralregistra-
tionsystem.WeusedStataversion10forthestatistical
analyses. For mortality, we present deaths and obser-
vation time together with hazard rate ratios and Wald
95% confidence intervals estimated from a Cox pro-
portional hazards model with age as the underlying
time variable. P values were calculated from Wald
tests. As in previous survival analyses, we label these
mortality hazards rate ratios as mortality rate ratios.
Using time since inclusion as the underlying time
madevirtuallynodifferencetotheresults.Weassessed
the proportional hazards assumption graphically and
tested it by using Schoenfeld residuals (P=0.70). We
adjusted for age as inherent in the Cox model and for
district by stratification. We used the Kaplan-Meier
method to calculate accumulated mortality curves for
groupsAand B+C,bothoveralland stratifiedby birth
cohort.
In the intention to treat analysis, children were fol-
lowed from enrolment to 36 months of age or until
censoring due to movement or death, irrespective of
whether the child received measles vaccine at
9monthsofage.Intheperprotocolanalyses,weexam-
ined the mortality of all children from enrolment at 4.
5 months of age to the 9 month vaccination and mor-
tality between 9 and 36 months of age for the children
who received measles vaccine at 9 months of age. As
we compared different strains of measles vaccine, we
needed to provide the measles vaccine to know what
strainhadbeenprovided,sowecensoredchildrenwho
had received measles vaccine elsewhere. An overall
per protocol estimate between 4.5 and 36 months of
age came from censoring children not receiving
RESEARCH
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intention to treat and per protocol analyses were the
samebetween4.5and9 monthsofage; the onlydiffer-
ence was that children who did not receive measles
vaccine from us at 9 months of age were included in
theintentiontotreatbutnotintheperprotocolanalysis
from 9 to 36 months of age.
Exclusions
In the initial phase of the trial, 80 children had had
measles infection before enrolment at 4.5 months of
age (five died). Furthermore, the protocol specified
that children should be enrolled four weeks after the
third DTP vaccination. However, in the first month, a
programming error meant that 131 children were
enrolled within 25 days of the third DTP vaccination
(seven died). Furthermore, we excluded 18 children
because they were enrolled twice (none died); this
may happen if the child has been registered with two
identification numbers because the mother and the
father live in different places or because the child
oftenstayswithagrandparent;weexcludedthesechil-
dren from the study. We excluded two children who
had the wrong age recorded; they were both one year
older than originally assumed (neither died). As in the
previous analysis,
26 we excluded these 231 children
from the main analysis. A further 17 children received
the wrong type of measles vaccine at 9 months of age
and they have been censored in the analysis from the
date of this vaccination (none died).
RESULTS
Participants
ThenumberofchildrenenrolledbetweenAugust2003
and April 2007 was 6648 (fig 1), and we included 6417
in the main analysis. Of these, 2129 were randomised
to Edmonston-Zagreb measles vaccine at 4.5 and
9 months of age and 4288 were randomised to receive
no vaccine at 4.5 months of age and Edmonston-
Zagreb or Schwarz measles vaccine at 9 months of
age. The study ended in October 2009 when the last
children became 3 years of age.
At 9 months of age, 64 (1%) had died, 216 had
moved, 167 were travelling throughout the period up
to 18 months of age, 29 were not visited because of
administrative errors in the printing of the 9 months
examination forms, 281 had already received a
measles vaccine elsewhere, and 17 refused to partici-
pate.Afurther17receivedthewrongvaccineandwere
therefore censored at 9 months of age (fig 1). There-
fore, 5626 children took part in the last part of the
study from 9 to 36 months of age. The proportion of
children who had received measles vaccine elsewhere
differed between group A and groups B and C (fig 1).
Baseline data
No major differences existed in the demographic,
socioeconomic, and health related background factors
between children included in the early two dose
measles vaccine arm (group A) and the two groups
with measles vaccine at 9 months of age (groups B
+C) (table 1).
Outcomes
Main results
WefoundnodifferenceinmortalitybetweengroupsB
and C from 4.5 to 36 months of age; the intention to
treat and per protocol mortality rate ratios were 1.01
(95%confidenceinterval0.74to1.37)and0.99(0.72to
1.35) for Edmonston-Zagreb vaccine (78/2153 chil-
dren) compared with Schwarz vaccine (81/2135 chil-
dren). From 9 to 36 months of age after measles
vaccination, the per protocol mortality rate ratio was
1.09(0.75to1.59)forEdmonston-Zagrebvaccine(57/
1841 children) compared with Schwarz vaccine (54/
1825 children).
The effect of early two dose measles vaccine (group
A) was similar when compared with Edmonston-
Zagreb measles vaccine at 9 months of age (group B:
mortality rate ratios 0.79 (0.57 to 1.09) for intention to
treat analysis and 0.71 (0.50 to 1.00) for per protocol
analysis) or with Schwarz measles vaccine at 9 months
ofage(groupC:mortalityrateratios0.78(0.57to1.08)
for intention to treat and 0.69 (0.49 to 0.96) for per
protocol) (web tables B and C). As we found no differ-
ences in the pattern of mortality, we combined groups
B and C as a control group for the comparison with
early measles vaccine (group A) (table 2).
Table 2showsthatchildrenassignedtoanearlytwo
dose measles vaccine schedule between 4.5 and
36 months of age had insignificantly lower mortality
in the intention to treat analysis (mortality rate ratio
0.78 (0.59 to 1.05)). In the per protocol analysis the
mortality rate ratio was 0.70 (0.52 to 0.94) (fig 2).
Secondary results
Inboththeintentiontotreatandperprotocolanalyses,
the mortality rate ratio was 0.67 (0.38 to 1.19) between
4.5 and 9 months. Between 9 and 36 months of age it
was 0.83 (0.59 to 1.16) in the intention to treat analysis
and 0.71 (0.50 to 1.01) in the per protocol analysis. In
theintentiontotreatanalysis,theeffectwasstatistically
significant for girls (mortality rate ratio 0.64 (0.42 to
0.98)) but not for boys (mortality rate ratio 0.95 (0.64
to1.42)),buttherelativeeffectwasnotsignificantlydif-
ferent for girls compared with boys (female:male esti-
materatio0.68(0.38to1.20);P=0.18).Similarly,inthe
per protocol analysis, the effect of early measles vacci-
nation wassignificant forgirls(mortalityrate ratio0.59
(0.38to0.91))butnotforboys(mortalityrateratio0.82
(0.54 to 1.25)) (female:male estimate ratio 0.71 (0.39 to
1.30); P=0.27) (table 2). After censoring for measles
infection, the mortality rate ratio was 0.84 (0.63 to
1.12) in the intention to treat analysis and 0.74 (0.55
to 1.00) in the per protocol analysis. The effect of
early measles vaccination on mortality from 4.5 to
36 months of age was not significantly better for chil-
drenenrolledduringthe dryseasonfromDecemberto
May (mortality rate ratios 0.74 (0.48 to 1.13) for inten-
tion to treat and 0.62 (0.40 to 0.98) for per protocol)
than during the rainy season from June to November
(mortality rate ratios 0.83 (0.56 to 1.22) for intention to
treat and 0.76 (0.51 to 1.14) for per protocol).
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and participants wereenrolled by the sameteamat the
threehealth centres coveringthese districts.The bene-
ficial effect of early measles vaccination tended to be
largestinCuntum,whichhadnottakenpartinthefirst
trial of vitamin A supplementation at birth (see below)
(web table D). We adjusted the main results for district
by stratification; web table D shows unadjusted esti-
mates. Little difference existed between adjusted and
unadjusted estimates.
Interactions with campaigns and other interventions
The cohort was exposed to a large number of cam-
paigns(table 1). Wefoundnosignofdifferentialparti-
cipation in these campaigns. We therefore did the
analyses censoring for participation in the campaigns
onebyonetoseewhetherthismodifiedtheeffectofthe
intervention.Ingeneral,censoringhadnoeffectonthe
estimatedeffectofearlytwodosemeaslesvaccinefrom
4.5 to 36 months of age (web table A).
We also tested whether the effect of early measles
vaccinewasthesamewithinthetreatmentarmsofcon-
current trials. That was not the case within the trials of
vitamin A supplementation at birth. A total of 5142
study children had taken part in these trials. The mor-
tality rate ratio for early measles vaccine versus
measles vaccine at 9 months of age differed signifi-
cantlyaccordingtostatusinthetrialsofvitaminAsup-
plementation at birth (web tables E and F) (P=0.011,
test for interaction of vitamin A supplementation at
birth and early measles vaccine). In the intention to
treat analysis, the mortality rate ratio for early measles
vaccination was 1.07 (0.71 to 1.61) for the 3015
childrenwhohadreceivedvitaminAsupplementation
at birth: 0.82 (0.44 to 1.53) for girls and 1.34 (0.78 to
2.29) for boys. Among the 2127 children who had
received placebo at birth, the mortality rate ratio was
0.45(0.24to0.84):0.40(0.17to0.96)forgirlsand0.52
(0.21 to 1.29) for boys. Compared with children who
receivedplaceboatbirth,neonatalvitaminAwasasso-
ciated with 2.5-fold higher mortality for children who
received measles vaccine at 4.5 and 9 months of age
(mortalityrateratio 2.59(1.24 to5.42)).The1275chil-
drennotenrolledinthe trialsofvitaminAsupplemen-
tation at birth had lower weight at enrolment and
highermortalityduringfollow-up;thisgroupincluded
children who had travelled and received the first BCG
Table 2 |Mortality rates and mortality rate ratios (with 95% confidence intervals) of recipients of early two dose measles vaccine (group A) compared with
measles vaccine at 9 months (groups B+C) among all children (n=6417)
Age interval
ITT mortality per 100 person years
(deaths/person days)
ITT mortality rate
ratio (A/(B+C))
ITT mortality rate ratio
(A/(B+C)) (with censoring
for measles infection)
PPmortalityrateratio
(A/(B+C))
PP mortality rate ratio
(A/(B+C)) (with censoring
for measles infection)
Early two dose measles
vaccine (group A)
Measles vaccine
at 9 months
(groups B and C)
4.5-9 months:
Boys 2.6 (10/142 341)
(n=1084)
2.7 (21/282 932)
(n=2151)
0.94 (0.44 to 2.01) 1.22 (0.55 to 2.70) 0.94 (0.44 to 2.01) 1.22 (0.55 to 2.70)
Girls 1.6 (6/137 245)
(n=1045)
3.5 (27/279 399)
(n=2137)
0.46 (0.19 to 1.11) 0.51 (0.21 to 1.25) 0.46 (0.19 to 1.11) 0.51 (0.21 to 1.25)
All 2.1 (16/279 586)
(n=2129)
3.1 (48/562 331)
(n=4288)
0.67 (0.38 to 1.19) 0.80 (0.45 to 1.43) 0.67 (0.38 to 1.19) 0.80 (0.45 to 1.43)
9-36 months:
Boys 1.2 (26/762 500)
(n=1047)
1.3 (54/1 506 371)
(n=2080)
0.95 (0.60 to 1.52) 0.99 (0.62 to 1.59) 0.78 (0.47 to 1.28) 0.79 (0.48 to 1.31)
Girls 1.1 (23/744 638)
(n=1012)
1.6 (63/1 476 049)
(n=2053)
0.72 (0.45 to 1.17) 0.73 (0.45 to 1.19) 0.64 (0.39 to 1.07) 0.65 (0.39 to 1.09)
All 1.2 (49/1 507 138)
(n=2059)
1.4 (117/2 982 420)
(n=4133)
0.83 (0.59 to 1.16) 0.85 (0.61 to 1.19) 0.71 (0.50 to 1.01) 0.72 (0.50 to 1.03)
4.5-36 months:
Boys 1.5 (36/904 841)
(n=1084)
1.5 (75/1 789 303)
(n=2151)
0.95 (0.64 to 1.42) 1.05 (0.70 to 1.57) 0.82 (0.54 to 1.25) 0.90 (0.59 to 1.37)
Girls 1.2 (29/881 883)
(n=1045)
1.9 (90/1 755 448)
(n=2137)
0.64 (0.42 to 0.98) 0.67 (0.44 to 1.02) 0.59 (0.38 to 0.91) 0.61 (0.39 to 0.95)
All 1.3 (65/1 786 724)
(n=2129)
1.7 (165/3 544 751)
(n=4288)
0.78 (0.59 to 1.05) 0.84 (0.63 to 1.12) 0.70 (0.52 to 0.94) 0.74 (0.55 to 1.00)
ITT=intention to treat analysis; PP=per-protocol analysis (between 4.5 and 9 months of age PP and ITT are the same analysis).
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Fig 2 | Kaplan-Meier accumulated mortality curves according
to vaccination group in intention to treat analysis.
MRR=mortality rate ratio
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lowbirthweightchildrenwereincludedinthisgroupas
the vitamin A supplementation trials initially included
only normal birthweight children. The mortality rate
ratioofearlymeaslesvaccineversusmeaslesvaccineat
9monthsofageinthisgroupofchildrenwas0.74(0.42
to 1.30); the ratio was 0.71 (0.33 to 1.51) for girls and
0.79 (0.35 to 1.80) for boys (web table G). Vitamin A
supplementationatbirthisnotofficialWHOpolicy,so
we did the survival analysis of measles vaccine sepa-
rately forthe 3402 childrenwho had not receivedvita-
min A supplementation at birth—that is, the children
whohadreceivedplacebointhevitaminAsupplemen-
tation trials and the children who had not participated.
Main results for children who did not receive vitamin A at
birth—Between 4.5 and 36 months of age, the early two
dosemeaslesvaccinegroup(A)comparedwithEdmon-
ston-Zagreb measles vaccine (group B) had mortality
rate ratios of 0.59 (0.37 to 0.93) in the intention to treat
analysis and 0.49 (0.30 to 0.80) in the per protocol ana-
lysis (web table H). Compared with Schwarz measles
vaccine (group C), the mortality rate ratios were 0.59
(0.37 to 0.94) in the intention to treat analysis and 0.51
(0.32 to 0.84) in the per protocol analyses (web table I).
Combining the two standard measles vaccine groups,
the mortality rate ratios were 0.59 (0.39 to 0.89) in the
intention to treat analysis and 0.50 (0.32 to 0.78) in the
per protocol analysis. Control for background factors
(table 1) had no effect on the mortality estimate for
early measles vaccine in the subgroup analysis of chil-
dren who had not received vitamin A at birth.
Secondary results for children who did not receive vitamin A
at birth—In the intention to treat and per protocol ana-
lyses, the mortality rate ratio was 0.33 (0.13 to 0.86)
between 4.5 and 9 months and 0.68 (0.43 to 1.08) and
0.56 (0.34 to 0.93) between 9 and 36 months of age
(table 3). In the intention to treat analysis, the effect
between 4.5 and 36 months of age was statistically sig-
nificant for girls (mortality rate ratio 0.54 (0.31 to 0.95))
but not for boys (mortality rate ratio 0.65 (0.36 to 1.20))
(female:male estimate ratio 0.83 (0.36 to 1.90); P=0.65).
Similarly, in the per protocol analysis, the effect was sig-
nificant for girls (mortality rate ratio 0.47 (0.26 to 0.86))
but not for boys (mortality rate ratio 0.55 (0.29 to 1.06))
(female:male estimate ratio 0.84 (0.35 to 2.04); P=0.71)
(table 3). The effect did not differ by season. After cen-
soring for measles infection, the mortality rate ratios
between 4.5 and 36 months of age became 0.65 (0.43
to 0.99) in the intention to treat analysis and 0.55 (0.35
to 0.86) in the per protocol analysis. As subclinical
measles infection at the start of the trial could have
played a role,
27 we did an analysis that included only
the 2037 children born after the end of the measles epi-
demic(May2004).Themortalityrateratiosforearlytwo
dosemeaslesvaccineversusmeaslesvaccineat9months
of age were 0.56 (0.30 to 1.04) in the intention to treat
analysis and 0.52 (0.28 to 0.99) in the per protocol ana-
lysis between 4.5 and 36 months of age in this group.
Figure 3 shows that, although the mortality level was
much lower for children born after the epidemic, the
differential pattern in mortality for children receiving
early two dose measles vaccine and standard measles
vaccineat9monthsofagewasthesameinbothcohorts.
DISCUSSION
This is one of the first trials of childhood vaccination
with individual randomisation to measure the effect of
a vaccine on all cause mortality. We had hypothesised
a 25% reduction in mortality between 4.5 and
36 months of age but observed only a 22% (95% con-
fidenceinterval −5% to 41%) reduction, which wasnot
statisticallysignificantin the intention totreatanalysis.
Theperprotocolanalysissuggesteda30%(6%to48%)
reduction in mortality. Among the secondary out-
comes, the reduction in mortality between 4.5 and
36 months of age was statistically significant for girls
inboththeintentiontotreatandperprotocolanalyses.
Wedidnotfindthiseffectforboys,butthedifferencein
effect between girls and boys was not statistically sig-
nificant. The study was not powered to test significant
differentialeffectsbetweensubgroupsinthesecondary
analyses. The analysis of possible interactions with
other trials and campaigns suggested that vitamin A
supplementation at birth may have a negative influ-
ence on the effect of early measles vaccination.
Strengths and weaknesses
Thisis the first trialdesignedto testa non-specific ben-
eficialeffectofmeaslesvaccinethatmayprovidesome
supportforsucheffects,atleastforgirls.Wehavedone
oneprevioustrialoftwodosemeaslesvaccinewiththe
same objective, but it did not give similar results; this
lack of effect was probably because we had not con-
trolled for the effect of subsequent DTP
vaccinations.
25 To prevent this problem in this trial,
we stipulated that the children should have received
the third DTP vaccine before being enrolled.
26 We
also considered in our analyses the children’s partici-
pationinthemajorcampaignsinthestudyareaduring
the trial period.
Ameaslesepidemicoccurredatthebeginningofthe
trial,andthiscouldbeconsideredbothastrengthanda
weakness. It permitted us to document that early
measles vaccination at 4.5 months of age was highly
effective and would serve the targeted purpose of pre-
venting measles infection.
26 On the other hand, one
could speculate that the non-specific beneficial effect
of early measles vaccination was due to prevention of
(undetected) cases of subclinical measles infection.
However, subclinical measles infection may not be
associated with increased mortality,
33 and in this
study we were able to show that the effect of early
measles vaccination was the same in the cohort born
after the measles epidemic (fig 3). Hence, consistent
with many previous studies,
57112434 the trial could be
seenassupportingthe hypothesisthatmeaslesvaccine
has a beneficial effect on non-measles related child-
hood mortality.
From the perspective of a randomised trial, this
study had several limitations, the most important of
whichwasthelackofblindingofthevaccinationstatus.
Mothers bring children’s vaccination cards to
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fication and because it entitles their children to free
consultationsand essentialdrugs.However, the health
workers,doctors,andnursesinthepaediatricwardand
at the health centres do not inspect the vaccination
cards of sick children to guide the treatment, and they
were not aware of the purpose of the study. Their clin-
icaldecisionsarethusunlikelytohaveaffectedsurvival
in a systematic way to the benefit of children who had
received measles vaccine early. If vaccination status
had affected treatment practice, it should also have
affected the survival of children who had received
measles vaccine at 4.5 months of age and vitamin A
supplementation at birth, as the randomisation to vita-
min A supplementation or placebo was blind. As this
wasnotthecase,wehavenoreasontothinkthatbiased
clinical decisions affected the outcome of the trial.
Secondly, the study was not perfectly balanced with
respect to drop-out. As we tested specific strains of
measles vaccine, children who had received measles
vaccine elsewhere before they attended the 9 month
vaccinationsessionwerecensoredinthestudybecause
the strain and quality of their measles vaccine would
not be known. We excluded more children at the
9 month vaccination session in groups B and C than
in group A (fig 1). Assuming that these early measles
vaccinations in groups B and C also had a beneficial
effect, they would have lowered the mortality rate in
group B and C and reduced the estimated beneficial
effect of early measles vaccine (group A) between 4.5
and 9 months of age. On the other hand, censoring
these children in the per protocol survival analysis
may have removed a group with low mortality from
groups B and C and therefore enhanced the estimated
beneficial effect of group A between 9 and 36 months
ofage.Thisispartofthereasonfordifferencesbetween
theperprotocolandintentiontotreatanalyses.Testing
modifications in vaccination strategy for vaccines that
are already available in routine use is difficult because
the trial itself may have an effect on how the current
routine vaccination is implemented. In this trial, the
fact that we focused on measles vaccination and early
measles vaccination may have meant that more chil-
dreninthecontrolgroupreceivedearlymeaslesvacci-
nation. The “true” estimate of the effect of early
measles vaccination as a public health intervention
may therefore be difficult to assess but is presumably
somewherebetweenthe intention to treatand per pro-
tocol estimates. For girls, for whom we hypothesised a
strong beneficial effect, both intention to treat and per
protocol estimates were statistically significant.
Thirdly,thecohortwasaffectedbymanyotherinter-
ventions,asiscommoninlowincomecountries.From
a public health perspective, examining the potential
effect of these other interventions on the trial inter-
vention would seem to be important.
Critical features of intervention
As regards the intervention, firstly, as pointed out
above, the results depend on the fact that all children
received the third DTP vaccine before entering the
trial.
26 Secondly, we also ensured that a gap of four
weeksormoreexistedbetweenthethirdadministration
ofDTPvaccineandenrolmentinthetrial.Previousstu-
dies have suggested that a short interval between these
vaccines is associated with increased mortality,
35 and
administration of measles vaccine and DTP vaccine at
the same time has been linked to negative health
outcomes.
36-38 Thirdly, these results apply only to
Edmonston-Zagreb measles vaccine,
39 which may be
more effective in the presence of maternal antibodies
than is the Schwarz stain of measles vaccine.
13
Wemustemphasisethatthebeneficialeffectforgirls
is related to these conditions. Measles vaccine will not
necessarily always have a beneficial effect.
36-38 Fortu-
nately, this trial suggests that the beneficial effect of
early two dose measles vaccine for girls is affected
only to a limited extent by season and by other vacci-
nation and vitamin A supplementation campaigns.
However, vitamin A supplementation at birth may
negate the beneficial effect of early measles vaccine.
Consistency with previous studies
For children who had not received vitamin A at birth,
thistrialisconsistentwithstudiesdoneinthe1970sand
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Fig 3 | Kaplan-Meier accumulated mortality curves according
to vaccination group and birth cohort in intention to treat
analysis in children without vitamin A supplementation at
birth. MRR=mortality rate ratio. 1365 children in cohort born
before June 2004: 444 randomised to two dose group and 921
to one dose group. 2037 children in cohort born after June
2004: 663 randomised to two dose group and 1374 to one
dose group
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mortality by 40% or more.
1-7 These studies were done
before DTP vaccination was introduced and before
vitamin A supplementation was used. Our trial sug-
gests at least two different pathways by which early
two dose measles vaccine may reduce mortality.
Firstly, in the age group from 4.5 to 9 months of age,
the children randomised to measles vaccine tended to
have lower mortality than the children who had the
third DTP vaccine as their most recent vaccine. A few
previous randomised trials have supported the hypoth-
esisthatearlymeaslesvaccinewasassociatedwithlower
mortalitybeforetheageofstandardmeaslesvaccination.
In a small randomised trial in Sudan, in which children
were given measles vaccine at 5 months of age and con-
trolsreceivedmeningococcalvaccines,thechildrenvac-
cinated for measles had a 91% lower mortality until the
controlchildrenreceivedmeaslesvaccineat9monthsof
age (mortality rate ratio 0.09 (0.01 to 0.71)).
40 In Bissau,
we did an unplanned randomised trial owing to a war
that stopped all vaccinations: the children who had
been randomised to measles vaccine at 6 months just
before the war had 70% lower mortality during the war
thandidthechildrenwhohadbeenrandomised toinac-
tivated polio vaccine at 6 months of age (mortality rate
ratio0.30(0.08to0.87)).
24Inthesestudies, DTP vaccine
was not administered at the same time as measles
vaccine,
122440 and the reduction in mortality was not
related to prevention of measles infection.
2440
Secondly, although the results did not reach statisti-
cal significance, having received two doses by
9 months of age may also have been associated with
better survival between 9 months and 36 months of
age than having the first measles vaccine at 9 months
of age as currently recommended. Previous studies
have also indicated that two doses of measles vaccine
by 9 months may be better than just one dose at
9 months. We used measles vaccine at 6 to 8 months
of age in campaigns in Bissau before 9 months was
defined as the official WHO policy. Campaigns were
annual or biannual, so whether a child was vaccinated
at 6-8 or 9-11 months of age depended on the child’s
birthday in relation to when the campaign was
arranged and not on maternal selection bias. From
9 months to 5 years of age, the children vaccinated at
6-8 months had significantly lower mortality com-
pared with children who were vaccinated at
9-11 months of age. This beneficial effect was particu-
larlystrongamongchildrenwhoreceivedmeaslesvac-
cine twice; the mortality rate ratio was 0.41 (0.19 to
0.85).
41 More research is clearly needed into the possi-
ble mechanisms that could explain this observation.
Although vitamin A supplementation is adminis-
tered to reduce vitamin A deficiency, we have shown
in several observational and randomised studies in
Guinea-Bissau and Ghana that vitamin A may interact
with vaccinations and enhance the non-specific effects
of vaccines.
30-3242-44 Vitamin A may interact benefi-
cially with measles vaccine administered alone and
negatively with DTP vaccine.
303242-44 Unexpectedly,
inthistrialneonatalvitaminAcomparedwithplacebo
atbirthwasassociatedwithtwofoldhighermortalityin
children who received measles vaccine at 4.5 months
of age. On the basis of previous studies that showed a
Table 3 |Mortality rates and mortality rate ratios of recipients of early two dose measles vaccine (group A) compared with measles vaccine at 9 months
(groups B+C) among children who had not received vitamin A supplementation at birth (n=3402)
Age interval
ITT mortality rate per 100 person years (deaths/
person days)
ITT mortality rate
ratio (A/(B+C))
ITT mortality rate ratio
(A/(B+C)) (with censoring
for measles infection)
PPmortalityrateratio
(A/(B+C))
PP mortality rate ratio
(A/(B+C)) (with censoring
for measles infection)
Early two dose measles
vaccine (group A)
Measles vaccine
at 9 months
(groups B and C)
4.5-9 months:
Boys 1.5 (3/73 603)
(n=558)
3.7 (15/147 459)
(n=1130)
0.36 (0.10 to 1.26) 0.47 (0.13 to 1.72) 0.36 (0.10 to 1.26) 0.47 (0.13 to 1.72)
Girls 1.0 (2/71 959)
(n=549)
3.4 (14/152 480)
(n=1165)
0.30 (0.07 to 1.31) 0.37 (0.08 to 1.68) 0.30 (0.07 to 1.31) 0.37 (0.08 to 1.68)
All 1.3 (5/145 562)
(n=1107)
3.5 (29/299 939)
(n=2295)
0.33 (0.13 to 0.86) 0.42 (0.16 to 1.12) 0.33 (0.13 to 0.86) 0.42 (0.16 to 1.12)
9-36 months:
Boys 1.0 (11/401 246)
(n=540)
1.3 (27/783 132)
(n=1086)
0.79 (0.39 to 1.59) 0.86 (0.42 to 1.75) 0.64 (0.30 to 1.38) 0.68 (0.31 to 1.46)
Girls 1.2 (13/386 943)
(n=531)
2.0 (43/794 503)
(n=1117)
0.62 (0.33 to 1.15) 0.63 (0.34 to 1.18) 0.52 (0.27 to 1.02) 0.53 (0.27 to 1.04)
All 1.1 (24/788 189)
(n=1071)
1.6 (70/1 577 635)
(n=2203)
0.68 (0.43 to 1.08) 0.71 (0.45 to 1.14) 0.56 (0.34 to 0.93) 0.58 (0.35 to 0.96)
4.5-36 months:
Boys 1.1 (14/474 849)
(n=558)
1.6 (42/930 591)
(n=1130)
0.65 (0.36 to 1.20) 0.76 (0.41 to 1.41) 0.55 (0.29 to 1.06) 0.63 (0.33 to 1.22)
Girls 1.2 (15/458 902)
(n=549)
2.2 (57/946 983)
(n=1165)
0.54 (0.31 to 0.95) 0.58 (0.33 to 1.03) 0.47 (0.26 to 0.86) 0.50 (0.27 to 0.92)
All 1.1 (29/933 751)
(n=1107)
1.9 (99/1 877 574)
(n=2295)
0.59 (0.39 to 0.89) 0.65 (0.43 to 0.99) 0.50 (0.32 to 0.78) 0.55 (0.35 to 0.86)
ITT=intention to treat analysis; PP=per protocol analysis (between 4.5 and 9 months of age PP and ITT are the same analysis).
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vaccine,
42 we would have expected a beneficial effect.
However, we have previously found that vitamin A
administered simultaneously with measles vaccine
and DTP vaccine produced a negative effect.
42 The
response may have been changed in this trial because
onlyfourweekspassedbetweenthethirdDTPvaccine
and measles vaccination, whereas the gap between
these vaccines would normally be 4-5 months. In any
event,thistrialandseveralofourpreviousstudiesindi-
cate that immunomodulating interventions may inter-
act and have major unexpected effects on childhood
survival in low income countries.
1930-3242-44
Interpretation
Although it showed no overall effect in the main ana-
lysis,thistrialsuggestedanon-specificbeneficialeffect
of measles vaccine among girls who have not received
neonatalvitaminA.Whentheoveralleffectofmeasles
vaccine is compared with the effect after censoring for
measles infection, only around 10-20% of the reduc-
tion in mortality seems to be due to the prevention of
infectionwithmeaslesanddeathsfrommeasles.Thisis
consistent with the many previous observational stu-
dies that have shown that censoring for measles infec-
tion had little influence on the estimate of the effect of
measles vaccine on total mortality.
11 The observed
beneficial effect of early measles vaccine in girls thus
cannot be explained by the prevention of cases of
measles and deaths from measles.
Whenastrongeffectofmeaslesvaccine onchildhood
survival was reported in observational studies and com-
munity intervention trials in the 1980s and 1990s, this
was assumed to be due to selection bias or the fact that
measlesvaccinepreventednotonlymortalityfromacute
measlesbutalsothelongtermnegativeconsequencesof
measles infection.
945 We subsequently found that
measleshadnolongtermnegativeconsequencesinGui-
nea-Bissau, Senegal, and Bangladesh.
33344647 Many fac-
torssuggestthatselectionbiasisanunlikelyexplanation
fortheremarkableeffectofmeaslesvaccineonmortality
in observational studies.
71124
Thewaytoexplainthebeneficialnon-specificeffects
ofmeaslesvaccineforgirlsisthatearlymeaslesvaccine
reduces susceptibility to severe infections with patho-
gens other than measles virus. In this trial, children
vaccinated against measles had a significant reduction
inadmissiontohospital,particularlyadmissionsdueto
pneumonia, and this effect was strongest for girls
(unpublished data). We have previously observed
that the non-specific effects of vaccines seem to be
strongest for pneumonia.
48
Very few studies have examined the immunological
mechanisms that might explain the non-specific effects
ofvaccines,although studiesofheterologous immunity
in animals have shown that priming with one antigen
may either enhance or reduce susceptibility to subse-
quent infection with unrelated antigens.
4950 The obser-
vation that girls who received measles vaccine at 4.
5 monthsofagehada reductioninmortality compared
with girls who had the third DTP vaccine as their most
recent vaccine until 9 monthsofagecould berelated to
differences in immune priming of live and inactivated
vaccines. In animal studies of live and inactivated vac-
cinesofthe same antigen,the live vaccinehasgenerally
been associated with a better capacity to handle a sub-
sequent challenge.
51-55 Little is known about how these
effects influence the reaction to unrelated antigens.
Implications
WHO’s Global Advisory Committee on Vaccine
Safety has declared that it will keep a watch on the
non-specific effects of vaccines and has supported the
proposition that only randomised studies will provide
convincing evidence for or against non-specific effects
of vaccines on mortality.
56 This posed a dilemma, as
randomising children to vaccines that are already in
the routine schedule isnot usuallyconsidered accepta-
ble. However, by studying the early administration of
measles vaccine,we have been able to test the possible
non-specificeffectsofmeaslesvaccineinarandomised
trial. Measles vaccine tended to be associated with a
beneficial non-specific effect, as we had hypothesised,
but the overall result did not reach statistical signifi-
cance and should be interpreted with caution. How-
ever, we had also hypothesised that the effects would
be strongest for girls, and the trial suggests that bene-
ficial non-specific effects of measles vaccine are likely
for girls.
Surprisingly, we found an interaction between vita-
min A supplementation at birth and the effect of early
measles vaccination on mortality between 4.5 and
36 months of age; the beneficial effect was much stron-
ger among children who had not received vitamin A at
birth. As vitamin A at birth is not WHO policy, further
studies are needed to examine the possibility that we
may achieve substantial reductions in childhood mor-
tality in low income countries by giving an additional
dose of measles vaccine before 9 months of age to chil-
dren who have not received vitamin A at birth.
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intervention between girls and boys was not statistically significant
Prevention of measles infection explained only a small part of the effect on overall mortality
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 11 of 13provided the data on these children. Data were analysed by PA, AA, and
HR. AA andHRwereresponsibleforthestatisticalanalyses. PA wrote the
first draft ofthe paper, and all authors contributed to the final version. PA
is the guarantor.
Funding: The research on the decline in maternal antibodies that inspired
this trial was funded by the Thrasher Foundation. This study was mostly
funded by DANIDA and the Danish National Research Foundation. The
project also received support from Fonden til Lægevidenskabens
Fremme and Novo Nordisk Foundation. The Bandim Health Project
received support from DANIDA. PA holds a research professorship grant
from the Novo Nordisk Foundation. The funding agencies had no role in
thestudydesign,datacollection,dataanalysis,datainterpretation,orthe
writing of the report.
Competing interests: All authors have completed the Unified Competing
Interest form at www.icmje.org/coi_disclosure.pdf (available on request
from the corresponding author) and declare: no support from any
organisation for the submitted work; no financial relationships with any
organisations that might have an interest in the submitted work in the
previous 3 years; no other relationships or activities that could appear to
have influenced the submitted work.
Ethicalapproval:TheprotocolwasapprovedbytheDanishCentralEthical
Committee, the Gambia/MRC scientific and ethics committees, and the
Guinean Ministry of Health’s Research Coordination Committee.
Data sharing: No additional data available.
1 Kasongo Project Team. Influence of measles vaccination on survival
p a t t e r no f7 - 3 5 - m o n t h - o l dc h i l d r e ni nK a s o n g o ,Z a i r e .Lancet
1981;1:764-7.
2 Aaby P, Bukh J, Lisse IM, Smits AJ. Measles vaccination and child
mortality. Lancet 1981;ii:93.
3 AabyP,BukhJ,LisseIM,SmitsAJ.Measlesvaccinationandreduction
in child mortality: a community study from Guinea-Bissau. JI n f e c t
1984;8:13-21.
4D e s g r éesdu LoûA,PisonG, Aaby P.Theroleofimmunizations inthe
recent decline inchildhood mortality and thechangesin thefemale/
male mortality ratio in rural Senegal. Am J Epidemiol
1995;142:643-52.
5 A a b yP ,S a m bB ,S i m o n d o nF ,K n u d s e nK ,C o l lS e c kA M ,B e n n e t tJ ,
et al. Divergent mortality for male and female recipients of low-titre
and high-titre measles vaccines in rural Senegal. Am J Epidemiol
1993;138:746-55.
6 A a b yP ,B u k hJ ,L i s s eI M ,S m i t sA J ,G o m e sJ ,F e r n a n d e sM A ,e ta l .
Determinants of measles mortality in a rural area of Guinea-Bissau:
crowding, age, and malnutrition. JT r o pP e d i a t r1984;30:164-9.
7 A a b yP ,P e d e r s e nI R ,K n u d s e nK ,d aS i l v aM C ,M o r d h o r s tC H ,
Helm-Petersen NC, et al. Child mortality related to seroconversion or
lack of seroconversion after measles vaccination. Pediatr Infect Dis J
1989;8:197-200.
8 Holt EA, Boulos R, Halsey NA, Boulos IM, Boulos C. Childhood
survival in Haiti: protective effect of measles vaccination. Pediatrics
1990;85:188-94.
9 Clemens JD, Stanton BF, Chakraborty J, Chowdhury S, Rao M, Ali M.
Measles vaccination and childhood mortality in rural Bangladesh.
Am J Epidemiol 1988;128;1330-9.
10 Koenig MA, Khan MA, Wojtyniak B, Clemens JD, Chakraborty J,
Fauveau V, et al. The impact of measles vaccination upon childhood
mortality in Matlab, Bangladesh. Bull World Health Organ
1990;68:441-7.
11 Aaby P, Samb B, Simondon F, Coll Seck AM, Knudsen K, Whittle H.
Non-specific beneficial effect of measles immunisation: analysis of
mortality studies from developing countries. BMJ 1995;311:481-5.
12 Expanded Programme on Immunisation. The optimal age for
measles immunization. Wkly Epidemiol Rec 1982;57:89-91.
13 WhittleH,HanlonP,O’NeillK,HanlonL,MarshV,JuppE,etal.Trialof
high-dose Edmonston-Zagreb measles vaccine in the Gambia:
antibody response and side-effects. Lancet 1988;2:811-4.
14 Whittle H, Campbell H, Rahman S, Armstrong JRM. Antibody
persistence in Gambian children after high-dose Edmonston-Zagreb
measles vaccine. Lancet 1990;336:1048-51.
15 Aaby P, Jensen TG, Hansen HL, Kristiansen H, Thårup J, Poulsen A,
et al. Trial of high-dose Edmonston-Zagreb measles vaccine in
Guinea-Bissau: protective efficacy. Lancet 1988;2:809-11.
16 Aaby P, Knudsen K, Whittle H, Lisse IM, Thårup J, Poulsen A, et al.
Long-term survival after Edmonston-Zagreb measles vaccination in
Guinea-Bissau: increased female mortality rate. JP e d i a t r
1993;122:904-8.
17 Aaby P, Samb B, Simondon F, Knudsen K, Coll Seck AM, Bennett J,
et al. Sex-specific differences in mortality after high titre measles
immunization in rural Senegal. Bull World Health Organ
1994;72:761-70.
18 K n u d s e nK M ,A a b yP ,W h i t t l eH ,R o w eM ,S a m bB ,S i m o n d o nF ,e ta l .
Child mortality following standard, medium or high titre measles
immunization in West Africa. Int J Epidemiol 1996;25:665-73.
19 Aaby P, Jensen H, Samb B, Cisse B, Sodeman M, Jakobsen M, et al.
Differences in female-male mortality after high-titre measles vaccine
and association with subsequent vaccination with diphtheria-
tetanus-pertussis and inactivated poliovirus: reanalysis of West
African studies. Lancet 2003;361:2183-8.
20 Holt EA, Moulton LH, Siberry GK, Halsey NA. Differential mortality
measles vaccine titer and sex. JI n f e c tD i s1993;168:1987-96.
21 Expanded Programme on Immunization. Safety of high titre measles
vaccines. Wkly Epidemiol Rec 1992;67:357-61.
22 Garly ML, Martins CL, BaléC, da Costa F, Dias F, Whittle H, et al. Early
two-dose measles vaccination schedule in Guinea-Bissau: good
protection and coverage in infancy. Int J Epidemiol 1999;28:347-52.
23 Garly ML, Balé C, Martins C, Monteiro M, George E, Kidd M, et al.
Measles antibody responses after early two dose trials in Guinea-
Bissau with Edmonston-Zagreb and Schwarz standard-titre measles
vaccine: better antibody increase from booster dose of the
Edmonston-Zagreb vaccine. Vaccine 2001;19:1951-9.
24 AabyP,GarlyML,BaléC,M art insC,J en se nH,LisseIM ,etal.S ur viv al
of previously measles-vaccinated and measles-unvaccinated
c h i l d r e ni na ne m e r g e n c ys i t u a t i o n :a nu n p l a n n e ds t u d y .Pediatr
Infect Dis J 2003;22:798-805.
25 Aaby P, Garly ML, Jensen H, Martins C, Balé C, Benn CS, et al.
Inactivated polio and diphtheria-tetanus-pertussis vaccines
associated with increased female mortality prior to measles
vaccination: observations from vaccination trials in Guinea-Bissau.
Pediatr Infect Dis J 2007;26:247-52.
26 Martins CL, Garly ML, Balé C, Rodrigues A, Ravn H, Whittle HC, et al.
Protective efficacy of standard Edmonston-Zagreb measles
vaccination in infants aged 4.5 months: interim analysis of a
randomised clinical trial. BMJ 2008;337:a661.
27 M a r t i n sC ,B a l eC ,G a r l yM L ,R o d r i g u e sA ,L i s s eI M ,A n d e r s e nA ,e ta l .
Girls may have lower levels of maternal measles antibodies and
higherriskofsubclinicalmeaslesinfectionbeforetheageofmeasles
vaccination. Vaccine 2009;27:5220-5.
28 Aaby P. Bandim: an unplanned longitudinal study. In: Das Gupta M,
Aaby P, Pison G, Garenne M, eds. Prospective community studies in
developing countries. Oxford University Press, 1997:276-96.
29 Aaby P, Martins C, Bale C, Garly ML, Rodrigues A, Biai S, et al. Sex
differencesintheeffect ofvaccinesontheriskofhospitalisationdue
to measles in Guinea-Bissau. Pediatr Infect Dis J 2010;29:324-8.
30 Benn CS, Fisker A, Roth A, Diness BR, Lausch KR, Ravn H, et al.
RandomisedtrialofvitaminA supplementationand BCGvaccination
at birth to low-birth-weight children. BMJ 2010;340:c1101.
31 B e n nC S ,D i n e s sB R ,R o t hA ,N a n t eE ,F i s k e rA B ,L i s s eI M ,e ta l .E f f e c t
of50,000 IU vitaminA given with BCG vaccine onmortality ininfants
in Guinea-Bissau: randomised placebo controlled trial. BMJ
2008;336:1416-20.
32 Benn CS, Rodrigues A, Yazdanbakhsh M, Fisker AB, Ravn H,
Whittle H, et al. The effect of high-dose vitamin A supplementation
administered with BCG vaccine at birth may be modified by
subsequent DTP vaccination. Vaccine 2009;27:2891-8.
33 Aaby P, Samb B, Simondon F, Cisse B, Jensen H, Lisse IM, et al. Low
mortality after mild measles infection compared to uninfected
c h i l d r e ni nr u r a lW e s tA f r i c a .Vaccine 2002;21:120-6.
34 Aaby P, Bhuyia A, Nahar L, Knudsen K, Francisco A, Strong M. The
survival benefit of measles immunisation may not be explained
entirely by the prevention of measles disease. Int J Epidemiol
2003;32:106-15.
35 Garly ML, Trautner SL, Marx C, Danebod K, Nielsen J, Ravn H, et al.
Thymus size at 6 months of age and subsequent child mortality. J
Pediatr 2008;153:683-8.
36 Aaby P, Jensen H, Walraven G. Age-specific changes in female-male
mortality ratio related to the pattern of vaccinations: an
observational study from rural Gambia. Vaccine 2006;24:4701-8.
37 Aaby P, Vessari H, Nielsen J, Maleta K, Benn CS, Jensen H, et al. Non-
specific and sex-differential effects of routine immunizations in rural
Malawi. Pediatr Infect Dis J 2006;25:721-7.
38 Aaby P, Benn CS. Assessment of childhood immunisation coverage?
Lancet 2009;373:1428.
39 Bennett JV, Cutts FT, Katz SL. Edmonston-Zagreb measles vaccine: a
good vaccine with an image problem. Pediatrics 1999;104:1123-4.
40 Aaby P, Ibrahim S, Libman M, Jensen H. The sequence of
vaccinations and increased female mortality after high-titre measles
vaccine: trials from rural Sudan and Kinshasa. Vaccine
2006;24:2764-71.
41 Aaby P, Andersen M, Sodemann M, Jakobsen M, Gomes J,
Fernandes M. Reduced childhood mortality after standard measles
vaccination at 4-8 months compared with 9-11 months of age. BMJ
1993;307:1308-11.
42 BennCB, MartinsC,Rodrigues A,Fisker AB, Christoffersen D,Aaby P.
The effect of vitamin A supplementation administered with missing
RESEARCH
page 12 of 13 BMJ | ONLINE FIRST | bmj.comvaccines during national immunisation days in Guinea-Bissau. Int J
Epidemiol 2009;38:304-11.
43 Benn CS, Aaby P, Nielsen J, Binka FN, Ross DA. Does vitamin A
supplementation interact with routine vaccinations? An analysis of
the Ghana vitamin A supplementation trial. Am J Clin Nutr
2009;90:629-39.
44 Roth A, Benn CB, Ravn H, Rodrigues A, Lisse IM, Yazdanbakhsh M,
et al. A randomised trial of the effect of revaccination with BCG in
early childhood and mortality. BMJ 2010;340:c809.
45 Cooper WO, Boyce TG, Wright PF, Griffin MR. Do childhood vaccines
have non-specific effects on mortality? Bull World Health Organ
2003;81:821-6.
46 Aaby P, Lisse I, Mølbak K, Knudsen K, Whittle H. No persistent T
lymphocyte immunosuppression or increased mortality after
measles infection: a community study from Guinea-Bissau. Pediatr
Infect Dis J 1996;15:39-44.
47 Aaby P, Samb B, Andersen M, Simondon F. No long-term excess
mortality after measles infection: a community study from Senegal.
Am J Epidemiol 1996;143:1035-41.
48 Veir umJE,S odem annM ,B iaiS,Jak obse nM ,Hedeg aardK,Jen se nH,
et al. Routine vaccinations associated with divergent effects on
female and male mortality at the paediatric ward in Bissau, Guinea-
Bissau. Vaccine 2005;23:1197-204.
49 Shann F. Heterologous immunity and the non-specific effects of
vaccines: a major medical advance? Pediatr Infect Dis J
2004;23:555-8.
50 Welsh RM, Selin LH. No one is naïve: the significance of heterologus
T-cell immunity. Nat Rev Immunol 2002;2:417-26.
51 Lindblad EB, Elhay MJ, Silva R, Appelberg R, Andersen P. Adjuvant
modulation of immune responses to tuberculosis subunit vaccines.
Infect Immun 1997;65:623-9.
52 Barnard A, Mahon BP, Watkins J, Redhead K, Mills KH. Th1/Th2 cell
dichotomy inacquiredimmunity toBordetella pertussis: variablesin
the in vivo priming and in vitro cytokine detection techniques affect
the classification of T-cell subsets as Th1, Th2 or Th0. Immunology
1996;87:372-80.
53 Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG.
Priming immunization determines T helper cytokine mRNA
expression patterns in lungs of mice challenged with respiratory
syncytial virus. JI m m u n o l1993;151:2032-40.
54 Fischer JE, Johnson JE, Johnson TR, Graham BS. Pertussis toxin
sensitization alters the pathogenesis of subsequent respiratory
syncytial virus infection. JI n f e c tD i s 2000;182:1029-38.
55 MoranTM,ParkH,Fernandez-Sesma,SchulmanJL.Th2responsesto
inactivated Influenza virus can be converted to Th1 responses and
facilitate recovery from heterosubtypic virus infection. JI n f e c tD i s
1999;180:579-85.
56 MeetingofGlobalAdvisoryCommitteeonVaccineSafety,18-19June
2008. Wkly Epidemiol Rec 2008;83:287-92.
Accepted: 20 September 2010
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 13 of 13